OSTX Positive Sentiment
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
Key Takeaway: OS Therapies has announced that its FDA OST-HER2 Type D meeting has been elevated to a Type B Pre-BLA meeting. This advancement suggests a positive trajectory for the company as it prepares for a Biologics License Application. The elevation indicates increased regulatory engagement and support from the FDA.
Price reaction · baseline $1.57 (2026-03-06 close) · hit pre-market · clean, no other OSTX news in the window
day 0 close · peak
+8.9%
day 1
+3.8%
day 3
-3.2%
Market Sentiment Analysis
POSITIVE FACTORS
- FDA meeting elevated to Type B, indicating progress.
- OS Therapies is moving closer to a Biologics License Application (BLA).
- Positive regulatory engagement with the FDA.